ResMed, Inc. Hits 52-Week Low at USD 180.41 Amid Market Struggles

ResMed, Inc., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has recently reached a new 52-week low of USD 180.41 on June 2, 2026. This marks a significant decline, with the stock's performance over the past year showing a decrease of 13.63%. In contrast, the S&P 500 has experienced a robust gain of 28.2% during the same period, highlighting a notable divergence in market performance. ResMed's current market capitalization stands at USD 43,243 million, reflecting its position within the mid-cap category. The company's price-to-earnings (P/E) ratio is reported at 29.00, indicating how investors value its earnings relative to its share price. Additionally, ResMed offers a dividend yield of 3.17%, which may appeal to income-focused investors. The company's return on equity is a strong 23.77%, suggesting effective management of shareholder equity. However, with a price-to-book ratio of 6.84 and a debt-to-equity ratio of -0.12, these metrics provide insight into its financial structure and market valuation.